Sign Out
Divalproex Sodium should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Hepatotoxicity under PRECAUTIONS].
Divalproex Sodium is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA Polymerase γ (POLG; e.g. Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG- related disorder [see Hepatotoxicity under PRECAUTIONS].
Divalproex Sodium is contraindicated in patients with known hypersensitivity to the drug [see Multi-Organ Hypersensitivity Reactions under PRECAUTIONS].
Divalproex sodium is contraindicated in patients with known urea cycle disorders [see Hyperammonemia - Urea Cycle Disorders under PRECAUTIONS].
Divalproex sodium is contraindicated in the following situation: Treatment of epilepsy: In pregnancy unless there is no suitable alternative treatment [see PRECAUTIONS and USE IN PREGNANCY & LACTATION].
In women of childbearing potential, unless the measures for prevention of pregnancy as mentioned in PRECAUTIONS and USE IN PREGNANCY & LACTATION are met.
Divalproex sodium is contraindicated in patients with porphyria.
